Đánh giá hiệu quả phác đồ RMPV trong điều trị u lympho không Hodgkin nguyên phát thần kinh trung ương=Evaluation of the efficacy of RMPV regimen in treatment of primary central nervous system lymphoma

0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: Huyền Nga Đỗ, Thanh Tùng Nguyễn

Ngôn ngữ: vie

Ký hiệu phân loại:

Thông tin xuất bản: Tạp chí Y học Việt Nam (Tổng hội Y học Việt Nam), 2024

Mô tả vật lý: tr.77-82

Bộ sưu tập: Metadata

ID: 478215

Thêm vào giỏ

Đánh giá hiệu quả của phác đồ RMPV trên người bệnh u lympho không Hodgkin nguyên phát thần kinh trung ương. Đối tượng và phương pháp nghiên cứu: Nghiên cứu mô tả cắt ngang trên 30 người bệnh u lympho không Hodgkin nguyên phát thần kinh trung ương điều trị phác đồ RMPV tại Bệnh viện K từ tháng 05/2019 đến tháng 05/2024. Kết quả: Tuổi trung bình 57 tuổi, giới nam chiếm 53,3%, chỉ số toàn trạng 0-1 (73,3%)
dưới típ không tâm mầm chiếm 83,3%. Đánh giá cuối kì tỉ lệ đạt đáp ứng hoàn toàn là 43,3%
tỉ lệ đạt đáp ứng 1 phần là 30,0%
tỉ lệ bệnh ổn định hoặc tiến triển là 13,3%
tỉ lệ bệnh nhân gặp tác dụng không mong muốn chiếm 63,3%
tại thời điểm 3 năm tỷ lệ PFS là 70%, OS là 76,7%
đáp ứng với hóa trị là yếu tố có khả năng tiên lượng độc lập với PFS/OS. Kết luận: Phác đồ RMPV có hiệu quả cao kéo dài thời gian sống thêm cũng như an toàn cho người bệnh PCNSL.Evaluate the efficacy of RMPV regimen in PCNSL patients. Research subjects and methods: Cross-sectional descriptive study on 30 PCNSL patients treated with RMPV regimen at K Hospital from May 2019 to May 2024. Results: Average age was 57 years old, male accounted for 53.3%, PS 0-1 (73.3%). The rate of multifocal brain tumors accounted for 73.3%
DLBCL subtype non-GCB accounted for 83.3%. At the end of treatment, the complete response rate was 43.3%
The partial response rate was 30.0%
The rate of stable or progressive disease was 13.3%
The proportion of patients experiencing side effects accounted for 63.3%
At 3 years, the PFS rate was 70%, OS rate was 76.7%
Response to chemotherapy is an independent prognostic factor for PFS/OS. Conclusion: RMPV regimen is highly effective in prolonging survival time as well as being safe for PCNSL patients.

1. Đọc trực tuyến

1. Đọc trực tuyến

Tạo bộ sưu tập với mã QR